CSF Ubiquitin Levels Are Higher in Alzheimer’s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease

Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer’s disease (AD) and Creutzfeldt–Jakob disease (CJD). However, to date, no study explored this...

Full description

Saved in:
Bibliographic Details
Published inBiomolecules (Basel, Switzerland) Vol. 10; no. 4; p. 497
Main Authors Abu-Rumeileh, Samir, Oeckl, Patrick, Baiardi, Simone, Halbgebauer, Steffen, Steinacker, Petra, Capellari, Sabina, Otto, Markus, Parchi, Piero
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 25.03.2020
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer’s disease (AD) and Creutzfeldt–Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography−multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation.
AbstractList Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography-multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation.Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography-multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation.
Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography-multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls ( = 28) and in cases with prion disease ( = 84), AD ( = 38), and frontotemporal dementia (FTD) ( = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation.
Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography-multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation.
Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer's disease (AD) and Creutzfeldt−Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography−multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation.
Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer’s disease (AD) and Creutzfeldt–Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography−multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls (n = 28) and in cases with prion disease (n = 84), AD (n = 38), and frontotemporal dementia (FTD) (n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation.
Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of cerebrospinal fluid (CSF) free monoubiquitin in Alzheimer’s disease (AD) and Creutzfeldt–Jakob disease (CJD). However, to date, no study explored this biomarker across the heterogeneous spectrum of prion disease. Using a liquid chromatography−multiple reaction monitoring mass spectrometry, we investigated CSF free monoubiquitin in controls ( n = 28) and in cases with prion disease ( n = 84), AD ( n = 38), and frontotemporal dementia (FTD) ( n = 30). Furthermore, in CJD subtypes, we evaluated by immunohistochemistry (IHC) the relative extent of brain ubiquitin deposits. Prion disease and, to a lesser extent, AD subjects showed increased levels of CSF free monoubiquitin, whereas FTD cases had median protein values similar to controls. The biomarker showed a good to optimal accuracy in the differential diagnosis between NDs and, most interestingly, between AD and FTD. After stratification, according to molecular subtypes, sporadic CJD VV2 demonstrated significantly higher levels of CSF ubiquitin and more numerous brain ubiquitin deposits at IHC in comparison to the typical and most prevalent MM(V)1 subtype. Moreover, CSF ubiquitin correlated with biomarkers of neurodegeneration and astrogliosis in NDs, and was associated with disease stage but not with survival in prion disease. The differential increase of CSF free monoubiquitin in prion disease subtypes and AD may reflect common, though disease and time-specific, phenomena related to neurodegeneration, such as neuritic damage, dysfunctional proteostasis, and neuroinflammation.
Audience Academic
Author Capellari, Sabina
Oeckl, Patrick
Halbgebauer, Steffen
Steinacker, Petra
Baiardi, Simone
Abu-Rumeileh, Samir
Otto, Markus
Parchi, Piero
AuthorAffiliation 3 IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy
1 Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40138 Bologna, Italy; samir.aburumeileh@gmail.com (S.A.-R.); simone.baiardi6@unibo.it (S.B.); sabina.capellari@unibo.it (S.C.)
4 Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy
2 Department of Neurology, Ulm University Hospital, 89081 Ulm, Germany; patrick.oeckl@uni-ulm.de (P.O.); steffen.halbgebauer@uni-ulm.de (S.H.); petra.steinacker@uni-ulm.de (P.S.)
AuthorAffiliation_xml – name: 1 Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40138 Bologna, Italy; samir.aburumeileh@gmail.com (S.A.-R.); simone.baiardi6@unibo.it (S.B.); sabina.capellari@unibo.it (S.C.)
– name: 4 Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy
– name: 2 Department of Neurology, Ulm University Hospital, 89081 Ulm, Germany; patrick.oeckl@uni-ulm.de (P.O.); steffen.halbgebauer@uni-ulm.de (S.H.); petra.steinacker@uni-ulm.de (P.S.)
– name: 3 IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy
Author_xml – sequence: 1
  givenname: Samir
  orcidid: 0000-0003-0631-8506
  surname: Abu-Rumeileh
  fullname: Abu-Rumeileh, Samir
– sequence: 2
  givenname: Patrick
  orcidid: 0000-0002-7652-7023
  surname: Oeckl
  fullname: Oeckl, Patrick
– sequence: 3
  givenname: Simone
  surname: Baiardi
  fullname: Baiardi, Simone
– sequence: 4
  givenname: Steffen
  surname: Halbgebauer
  fullname: Halbgebauer, Steffen
– sequence: 5
  givenname: Petra
  surname: Steinacker
  fullname: Steinacker, Petra
– sequence: 6
  givenname: Sabina
  surname: Capellari
  fullname: Capellari, Sabina
– sequence: 7
  givenname: Markus
  orcidid: 0000-0003-4273-4267
  surname: Otto
  fullname: Otto, Markus
– sequence: 8
  givenname: Piero
  orcidid: 0000-0002-9444-9524
  surname: Parchi
  fullname: Parchi, Piero
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32218217$$D View this record in MEDLINE/PubMed
BookMark eNptkk1rFDEYgAep2Fp78ywBLz24mo-ZSeYiLFvXFlYUa8FbSDLv7KbMJNskU6gn7_4C_56_xGy3LVsxBBLyPu-TNx_Piz3nHRTFS4LfMtbgd9r6gWBc4rLhT4oDSomYUM6-7-3M94ujGC9xbiJ3yp4V-2wTpIQfFL9m53N0oe3VaJN1aAHX0Ec0DYBO7XIFAeXFaf9jBXaA8Ofn74hObAQVAaWVcpvoPHiXfIJh7YPq0QkM4JJVSLkWfYWuB5MyC-iTz9OxVwGdjzrdrGGT_CVY7-6VL4qnneojHN2Nh8XF_MO32elk8fnj2Wy6mJiSizRpGRVdZbRiqqS1qUsBmJimgXwJHRaqrDQVqqKaNkwziltatTXgWogWuADCDouzrbf16lKugx1UuJFeWXm74MNSqpCs6UEqQeq21g0mhJcdF1pDV5eM60q1BOomu95vXetRD9CafPZ8C4-kjyPOruTSX0tOaV0TngXHd4Lgr0aISQ42Guh75cCPUVImSoo5oyyjr7foUuXSrOt8NpoNLqc1IxUvxa3w1W5FD6Xcv3kG3mwBE3yMAboHhGC5-VVy91dlnP6DG5tUyu-Wd7f9_5P-Akjs0Q4
CitedBy_id crossref_primary_10_1016_j_nsa_2023_102438
crossref_primary_10_3389_fnins_2021_648743
crossref_primary_10_1016_j_neurobiolaging_2020_11_015
crossref_primary_10_1002_alz_13863
crossref_primary_10_3390_ijms23042051
crossref_primary_10_3390_cells9112476
crossref_primary_10_1080_17460794_2025_2480963
crossref_primary_10_1002_dad2_12402
crossref_primary_10_3390_medicina58040473
crossref_primary_10_1038_s41380_025_02939_9
crossref_primary_10_3390_neurolint16050079
Cites_doi 10.1602/neurorx.1.2.213
10.1212/WNL.0b013e31821103e6
10.1007/s00415-006-0472-9
10.1111/nan.12461
10.1186/s13195-017-0331-1
10.1016/B978-0-444-63945-5.00009-X
10.1038/s41593-018-0238-6
10.1189/jlb.0510316
10.1002/mds.27872
10.1007/s12035-018-1421-1
10.1111/bpa.12695
10.1002/pmic.200900246
10.1038/s41598-017-10922-w
10.1016/0006-8993(91)91692-T
10.3233/JAD-180409
10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W
10.1093/jb/mvq044
10.1016/0006-8993(94)91757-4
10.1002/mds.26987
10.1007/s00401-017-1683-0
10.1136/jnnp-2017-315942
10.1093/brain/awh249
10.1001/jamaneurol.2019.1071
10.1007/s00401-012-1002-8
10.1186/s13195-019-0533-9
10.1002/acn3.50980
10.1021/pr5006058
10.1016/S1474-4422(14)70090-0
10.1002/ana.20639
10.1093/brain/awr179
10.1212/WNL.0b013e31827f0fd1
10.1080/21678421.2016.1267768
10.1007/s00702-014-1304-1
ContentType Journal Article
Copyright COPYRIGHT 2020 MDPI AG
2020 by the authors. 2020
Copyright_xml – notice: COPYRIGHT 2020 MDPI AG
– notice: 2020 by the authors. 2020
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3390/biom10040497
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE


CrossRef

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2218-273X
ExternalDocumentID oai_doaj_org_article_a816d6b901174f78bbef6437b5ad1e69
PMC7226617
A631574817
32218217
10_3390_biom10040497
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Italy
GeographicLocations_xml – name: Italy
GrantInformation_xml – fundername: EU Joint Programme - Neurodegenerative Disease Research (JPND) networks
  grantid: PreFrontAls, Genfi-Prox (01ED1512)
– fundername: Ministero della Salute
  grantid: Ricerca Corrente
– fundername: German Federal Ministry of Education and Research
  grantid: FTLDc 01GI1007A
GroupedDBID 53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFKRA
AFPKN
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
EBD
ESX
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
IAO
IHR
KQ8
LK8
M1P
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RPM
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
PJZUB
PPXIY
PQGLB
5PM
PUEGO
ID FETCH-LOGICAL-c478t-d328f5cba3a426c648e01c99e049f08a45b28a52b293b320d25d6e0688de78e13
IEDL.DBID M48
ISSN 2218-273X
IngestDate Wed Aug 27 01:27:14 EDT 2025
Thu Aug 21 18:19:02 EDT 2025
Tue Aug 05 09:38:45 EDT 2025
Tue Jun 17 21:20:41 EDT 2025
Thu Apr 03 07:06:43 EDT 2025
Tue Jul 01 00:43:12 EDT 2025
Thu Apr 24 22:59:39 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords human prion disease
chitinase-3-like protein 1
Alzheimer’s disease
biomarkers
frontotemporal dementia
mass spectrometry
neurofilament ligh chain
Creutzfeldt–Jakob disease
ubiquitin
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c478t-d328f5cba3a426c648e01c99e049f08a45b28a52b293b320d25d6e0688de78e13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ORCID 0000-0003-0631-8506
0000-0002-9444-9524
0000-0002-7652-7023
0000-0003-4273-4267
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/biom10040497
PMID 32218217
PQID 2384207323
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_a816d6b901174f78bbef6437b5ad1e69
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7226617
proquest_miscellaneous_2384207323
gale_infotracmisc_A631574817
pubmed_primary_32218217
crossref_primary_10_3390_biom10040497
crossref_citationtrail_10_3390_biom10040497
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20200325
PublicationDateYYYYMMDD 2020-03-25
PublicationDate_xml – month: 3
  year: 2020
  text: 20200325
  day: 25
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Biomolecules (Basel, Switzerland)
PublicationTitleAlternate Biomolecules
PublicationYear 2020
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Morimoto (ref_29) 1996; 148
Parchi (ref_17) 2012; 124
Oeckl (ref_4) 2014; 13
Strong (ref_22) 2017; 18
Green (ref_18) 2007; 254
ref_14
Alafuzoff (ref_30) 2015; 122
Franceschini (ref_35) 2018; 44
Lattanzio (ref_27) 2017; 133
Blennow (ref_2) 2004; 1
ref_32
Kudo (ref_9) 1994; 639
Parchi (ref_16) 1999; 46
Franceschini (ref_28) 2017; 7
Corrado (ref_36) 2019; 56
Majetschak (ref_10) 2011; 89
Hillis (ref_21) 2011; 76
Pocchiari (ref_31) 2004; 127
Steinacker (ref_3) 2010; 10
Dubois (ref_19) 2014; 13
Kimura (ref_7) 2010; 147
Rascovsky (ref_20) 2011; 134
Wang (ref_8) 1991; 566
Armstrong (ref_23) 2013; 80
Capellari (ref_33) 2018; 10
Jucker (ref_1) 2018; 21
Baiardi (ref_34) 2017; 88
Respondek (ref_26) 2020; 35
Baiardi (ref_12) 2019; 29
Respondek (ref_24) 2017; 32
Steinacker (ref_13) 2019; 12
Brinkmalm (ref_6) 2019; 11
Mometto (ref_25) 2018; 66
Hansson (ref_5) 2017; 11
Iqbal (ref_11) 2005; 58
Zerr (ref_15) 2018; 153
References_xml – volume: 1
  start-page: 213
  year: 2004
  ident: ref_2
  article-title: Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
  publication-title: NeuroRx
  doi: 10.1602/neurorx.1.2.213
– volume: 76
  start-page: 1006
  year: 2011
  ident: ref_21
  article-title: Classification of primary progressive aphasia and its variants
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31821103e6
– volume: 254
  start-page: 901
  year: 2007
  ident: ref_18
  article-title: Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis
  publication-title: J. Neurol.
  doi: 10.1007/s00415-006-0472-9
– volume: 44
  start-page: 574
  year: 2018
  ident: ref_35
  article-title: Regional pattern of microgliosis in sporadic Creutzfeldt-Jakob disease in relation to phenotypic variants and disease progression
  publication-title: Neuropathol. Appl. Neurobiol.
  doi: 10.1111/nan.12461
– volume: 10
  start-page: 3
  year: 2018
  ident: ref_33
  article-title: The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias
  publication-title: Alzheimers Res Ther.
  doi: 10.1186/s13195-017-0331-1
– volume: 153
  start-page: 155
  year: 2018
  ident: ref_15
  article-title: Sporadic Creutzfeldt-Jakob disease
  publication-title: Handbook of Clinical Neurology
  doi: 10.1016/B978-0-444-63945-5.00009-X
– volume: 21
  start-page: 1341
  year: 2018
  ident: ref_1
  article-title: Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases
  publication-title: Nat Neurosci.
  doi: 10.1038/s41593-018-0238-6
– volume: 89
  start-page: 205
  year: 2011
  ident: ref_10
  article-title: Extracellular ubiquitin: Immune modulator and endogenous opponent of damage-associated molecular pattern molecules
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.0510316
– volume: 35
  start-page: 171
  year: 2020
  ident: ref_26
  article-title: Movement Disorder Society-Endorsed Progressive Supranuclear Palsy Study Group. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies
  publication-title: Mov Disord.
  doi: 10.1002/mds.27872
– volume: 56
  start-page: 5009
  year: 2019
  ident: ref_36
  article-title: Analysis of RNA Expression Profiles Identifies Dysregulated Vesicle Trafficking Pathways in Creutzfeldt-Jakob Disease
  publication-title: Mol Neurobiol.
  doi: 10.1007/s12035-018-1421-1
– volume: 29
  start-page: 278
  year: 2019
  ident: ref_12
  article-title: Recent advances in the histo-molecular pathology of human prion disease
  publication-title: Brain Pathol.
  doi: 10.1111/bpa.12695
– volume: 10
  start-page: 81
  year: 2010
  ident: ref_3
  article-title: Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease
  publication-title: Proteomics
  doi: 10.1002/pmic.200900246
– volume: 7
  start-page: 10655
  year: 2017
  ident: ref_28
  article-title: High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-10922-w
– volume: 566
  start-page: 146
  year: 1991
  ident: ref_8
  article-title: Brain ubiquitin is markedly elevated in Alzheimer disease
  publication-title: Brain Res.
  doi: 10.1016/0006-8993(91)91692-T
– volume: 66
  start-page: 551
  year: 2018
  ident: ref_25
  article-title: Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-180409
– volume: 46
  start-page: 224
  year: 1999
  ident: ref_16
  article-title: Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects
  publication-title: Ann. Neurol.
  doi: 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W
– volume: 147
  start-page: 793
  year: 2010
  ident: ref_7
  article-title: Regulatory mechanisms involved in the control of ubiquitin homeostasis
  publication-title: J. Biochem.
  doi: 10.1093/jb/mvq044
– volume: 639
  start-page: 1
  year: 1994
  ident: ref_9
  article-title: Alzheimer disease: Correlation of cerebro-spinal fluid and brain ubiquitin levels
  publication-title: Brain Res.
  doi: 10.1016/0006-8993(94)91757-4
– volume: 32
  start-page: 853
  year: 2017
  ident: ref_24
  article-title: Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
  publication-title: Mov. Disord.
  doi: 10.1002/mds.26987
– volume: 11
  start-page: 11
  year: 2017
  ident: ref_5
  article-title: Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer’s Disease and Parkinsonian Disorders
  publication-title: Proteomics Clin Appl.
– volume: 148
  start-page: 249
  year: 1996
  ident: ref_29
  article-title: Transient ischemia depletes free ubiquitin in the gerbil hippocampal CA1 neurons
  publication-title: Am. J. Pathol.
– volume: 133
  start-page: 559
  year: 2017
  ident: ref_27
  article-title: Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: Diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels
  publication-title: Acta Neuropathol.
  doi: 10.1007/s00401-017-1683-0
– volume: 88
  start-page: 764
  year: 2017
  ident: ref_34
  article-title: Towards an early clinical diagnosis of sporadic CJD VV2 (ataxic type)
  publication-title: J. Neurol. Neurosurg. Psychiatry
  doi: 10.1136/jnnp-2017-315942
– volume: 12
  start-page: 2
  year: 2019
  ident: ref_13
  article-title: CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia
  publication-title: Alzheimers Res Ther.
– volume: 127
  start-page: 2348
  year: 2004
  ident: ref_31
  article-title: Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies
  publication-title: Brain
  doi: 10.1093/brain/awh249
– ident: ref_32
  doi: 10.1001/jamaneurol.2019.1071
– volume: 124
  start-page: 517
  year: 2012
  ident: ref_17
  article-title: Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: An inter-rater study among surveillance centres in Europe and USA
  publication-title: Acta Neuropathol.
  doi: 10.1007/s00401-012-1002-8
– volume: 11
  start-page: 82
  year: 2019
  ident: ref_6
  article-title: Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
  publication-title: Alzheimers Res Ther.
  doi: 10.1186/s13195-019-0533-9
– ident: ref_14
  doi: 10.1002/acn3.50980
– volume: 13
  start-page: 4518
  year: 2014
  ident: ref_4
  article-title: Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer’s disease and frontotemporal lobar degeneration
  publication-title: J. Proteome Res.
  doi: 10.1021/pr5006058
– volume: 13
  start-page: 614
  year: 2014
  ident: ref_19
  article-title: Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70090-0
– volume: 58
  start-page: 748
  year: 2005
  ident: ref_11
  article-title: Subgroups of Alzheimer’s disease based on cerebrospinal fluid molecular markers
  publication-title: Ann Neurol.
  doi: 10.1002/ana.20639
– volume: 134
  start-page: 2456
  year: 2011
  ident: ref_20
  article-title: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
  publication-title: Brain
  doi: 10.1093/brain/awr179
– volume: 80
  start-page: 496
  year: 2013
  ident: ref_23
  article-title: Criteria for the diagnosis of corticobasal degeneration
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31827f0fd1
– volume: 18
  start-page: 153
  year: 2017
  ident: ref_22
  article-title: Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria
  publication-title: Amyotroph. Lateral Scler. Frontotemporal. Degener.
  doi: 10.1080/21678421.2016.1267768
– volume: 122
  start-page: 957
  year: 2015
  ident: ref_30
  article-title: Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: An inter-laboratory study by the BrainNet Europe consortium
  publication-title: J. Neural. Transm.
  doi: 10.1007/s00702-014-1304-1
SSID ssj0000800823
Score 2.2134955
Snippet Disturbances in the ubiquitin-proteasome system seem to play a role in neurodegenerative dementias (NDs). Previous studies documented an increase of...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 497
SubjectTerms Aged
Alzheimer Disease - cerebrospinal fluid
Alzheimer's disease
Analysis
Atomic properties
Biological markers
biomarkers
Biomarkers - cerebrospinal fluid
Brain - metabolism
Brain - pathology
Case-Control Studies
Cerebrospinal fluid proteins
chitinase-3-like protein 1
Comparative analysis
Creutzfeldt-Jakob Syndrome - cerebrospinal fluid
creutzfeldt–jakob disease
Female
Frontotemporal dementia
Frontotemporal Dementia - cerebrospinal fluid
human prion disease
Humans
Male
mass spectrometry
Measurement
Middle Aged
neurofilament ligh chain
Prion diseases
Prion Diseases - cerebrospinal fluid
Prion Diseases - pathology
Ubiquitin
Ubiquitin - cerebrospinal fluid
Ubiquitin - metabolism
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT70gaHkslMpIwAVFXTtx7ByXllWFKELASr1FfkzUoG0K-ziUE3d-AX-vv6QzcXaVCCEuXGM7cTJjzzeT8TeMvQjWI-gXWZKh_UAHRTg6rGwRyIEzvvIhkj2ffchPZ9m7c3XeK_VFOWGRHjh-uCNrRB5yRyckdVZp4xxU9LPJKRsE5O3RPbR5PWfqa4eDjExjpnuKfv0RnWYndjRExHpgg1qq_j835J5FGmZL9szP9B672-FGPonzvc_uQLPH9icN-syX1_wVbzM52xD5Pvt1_HnKZ67-vq5XdcPfU17QEocCj1kdHC9O5j8uoL6Exc3P30t-En_TcIqjU-u0pTXoaKvm_KSNIdaW2ybwT1BRqB_7Aj_bFNfluAFRNJcGf1ygrDe3fMBm07dfjk-TruhC4jNtVklIpamUdza1aLx9nhkYC18UgB-uGhubKYeyVNIhTnCpHAepQg5UuiaANiDSh2ynuWrgMePKyKBsYTTkeG8hbU5MQUXhhfZWChix1xsxlL5jJKfCGPMSPRMSWtkX2oi93Pb-Fpk4_tLvDUl024f4s9sLqFVlp1Xlv7RqxA5IH0pa5Tglj2vOl5M8FUqjZuMznm_0pKQmSlRr4Gq9LBEBZRK3TZmO2KOoN9uZ4N6J3hyN1gONGkx12NLUFy3lt5YEpPST__FuT9mupKDBOE2kOmA7q8UaniGyWrnDdhHdAg_zItE
  priority: 102
  providerName: Directory of Open Access Journals
Title CSF Ubiquitin Levels Are Higher in Alzheimer’s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease
URI https://www.ncbi.nlm.nih.gov/pubmed/32218217
https://www.proquest.com/docview/2384207323
https://pubmed.ncbi.nlm.nih.gov/PMC7226617
https://doaj.org/article/a816d6b901174f78bbef6437b5ad1e69
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxEB71IaFeEFCgCyUyEnBBgdj7sPeAUPqIKkSqqhApt5Xt9dJF6YZuEoly4s4v4O_xS5jZR0hUuHBd27vWesbzzXj8DcCzVFsE_TzoBmg_0EHhhi4rawRyziib2bQmex6eRiej4N04HG9AW220-YGzv7p2VE9qVE5efb26fosK_4Y8TnTZX9NFdSI-Q7ArN2EbbZIkFR02QP9zg4uU8OvM9xuDduAWyjUi7aps2R_zVLH439yrV4zVeiLlimUa3IHbDaRk_VoG7sKGK-7Bbr9Ad_rymr1gVZJnFT3fhR-HHwZsZPKrRT7PC_aeUoZmONSxOuGD4cP-5NuFyy9d-ev7zxk7qk9wGIXYqXVQMR40jFYTdlSFF3PNdJGyc5fRKQD2dWzY1t1luDdRoJcGn5UoBu0r78NocPzx8KTb1GPo2kCqeTf1hcpCa7Sv0a7bKFCux20cO_yHWU_pIDS4zKEwCCGML3qpCNPIUVWb1EnluP8Atopp4faAhUqkoY6VdBG-mwsdEYlQHFsurRbcefCyXYbENmTlVDNjkqDTQuuXrK6fB8-Xvb_UJB3_6HdAK7rsQ9Ta1YNp-SlpNDXRikdpZOhKrgwyqYxxGZ1umlCn3EWxB_skDwmJJE7JojrapB_5PJQo9PiNp62cJNREOWyFmy5mCYKjQOCOKnwPHtZys5xJK34eyDWJWpvqekuRX1Rs4FIQxpKP_nvkY9gRFETo-V0R7sPWvFy4J4i05qYDm3IsO7B9cHx6dt6p4hWdSrF-A37tLYQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CSF+Ubiquitin+Levels+Are+Higher+in+Alzheimer%E2%80%99s+Disease+than+in+Frontotemporal+Dementia+and+Reflect+the+Molecular+Subtype+in+Prion+Disease&rft.jtitle=Biomolecules+%28Basel%2C+Switzerland%29&rft.au=Abu-Rumeileh%2C+Samir&rft.au=Oeckl%2C+Patrick&rft.au=Baiardi%2C+Simone&rft.au=Halbgebauer%2C+Steffen&rft.date=2020-03-25&rft.pub=MDPI&rft.eissn=2218-273X&rft.volume=10&rft.issue=4&rft_id=info:doi/10.3390%2Fbiom10040497&rft_id=info%3Apmid%2F32218217&rft.externalDocID=PMC7226617
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-273X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-273X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-273X&client=summon